Equity Profile

RDY

Dr. Reddy's Laboratories Limited

Health CarePharmaceuticals$11.0B

May12Tue

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in India, focusing on producing a wide range of medications, including generics and active pharmaceutical ingredients....

Key Metrics to Watch

Revenue Growth

This metric will indicate how well the company is expanding its sales, which is crucial for assessing overall performance.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in India, focusing on producing a wide range of medications, including generics and active pharmaceutical ingredients. As a key player in the healthcare sector, it plays a significant role in providing affordable medicines to patients worldwide.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

In the last quarter, Dr. Reddy's continued to navigate challenges in the pharmaceutical market while focusing on expanding its product portfolio. The company has been working on enhancing its manufacturing capabilities to meet growing demand.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Dr. Reddy's upcoming earnings report are mixed, with investors looking for signs of revenue growth and profitability. The lack of analyst estimates adds uncertainty to the outlook.

Bull Case

If the company shows strong revenue growth and improved margins, it could signal a recovery and boost investor confidence.

Bear Case

Conversely, if the earnings report reveals declining sales or increased costs, it may lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue growth rate be for the quarter?

Revenue growth is critical for assessing the company's ability to expand and compete effectively in the market.

How has the company managed its cost structure in light of recent challenges?

Understanding cost management will provide insights into profitability and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dr. Reddy's ability to leverage its product pipeline, which could drive stronger-than-expected revenue growth this quarter.

Supporting Evidence

The options market is pricing an 8.11% move, indicating higher volatility expectations than historical averages.

Past earnings reactions show significant variability, suggesting that the market may not fully account for potential upside.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it reflects the company's ability to adapt to market conditions and manage costs.

Bull Confirmed If

A revenue growth rate of over 10% would confirm the bull case and indicate strong market demand.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case and raise concerns about the company's future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests the stock could rise by around 4.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with cautious commentary, the stock may see limited movement as investors assess future guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 8%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on cost management strategies and their effectiveness.
3Insights into market share changes in key regions.
4Comments on regulatory challenges and how they are being addressed.
5Future guidance on revenue expectations for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

RadNet, Inc.

Company Snapshot

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in India, focusing on producing a wide range of medications, including generics and active pharmaceutical ingredients....

Key Metrics to Watch

Revenue Growth

This metric will indicate how well the company is expanding its sales, which is crucial for assessing overall performance.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and will help investors gauge financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RDY Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

+0.00%

Avg Stock Reaction

-2.67%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company shows strong revenue growth and improved margins, it could signal a recovery and boost investor confidence.

Bear Case

Conversely, if the earnings report reveals declining sales or increased costs, it may lead to a negative reaction from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue growth rate be for the quarter?

Revenue growth is critical for assessing the company's ability to expand and compete effectively in the market.

How has the company managed its cost structure in light of recent challenges?

Understanding cost management will provide insights into profitability and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Dr. Reddy's ability to leverage its product pipeline, which could drive stronger-than-expected revenue growth this quarter.

Supporting Evidence

The options market is pricing an 8.11% move, indicating higher volatility expectations than historical averages.

Past earnings reactions show significant variability, suggesting that the market may not fully account for potential upside.

Key Risk

If revenue growth exceeds 10%, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be closely watched as it reflects the company's ability to adapt to market conditions and manage costs.

Bull Confirmed If

A revenue growth rate of over 10% would confirm the bull case and indicate strong market demand.

Bear Confirmed If

A revenue decline or stagnation would confirm the bear case and raise concerns about the company's future prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±8.11%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±8.1% while RDY has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

30d HV

31.2%

Calls (33K)P/C Ratio: 0.00Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

13.94%

of float

Insider

0.00%

of float

Holders

323

institutions

Top Holders· as of Mar 2026

Robeco Institutional Asset Management B.V.
17,177,882 sh · $234.8M
2.06%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dr. Reddy's beats expectations, history suggests the stock could rise by around 4.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with cautious commentary, the stock may see limited movement as investors assess future guidance.

Miss

A miss could lead to a decline, with historical patterns indicating a potential drop of around 8%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Details on cost management strategies and their effectiveness.
3Insights into market share changes in key regions.
4Comments on regulatory challenges and how they are being addressed.
5Future guidance on revenue expectations for the upcoming quarters.